官方服务：
资源简介：
Figure 4d. The quantitative data curves of immunohistochemical stain of VEGFin tumor-bearing mice treated with saline and cisplatin, respectively (n=3).
应用场景：
创建时间：
2015-01-01
相关数据集
An observational study of apatinib combined with XELOX regimen in postoperative adjuvant therapy of colorectal cancer
Interventions: experimental group:Apatinib combined with oxaliplatin and capecitabine (XELOX) g Primary outcome(s): Disease free survival Study Design: Single arm
NIAID Data Ecosystem80
Univariate analysis for progression-free survival and overall survival of biological and clinical parameters for the 45 ALK positive crizotinib-treated patients.
Abbreviation: PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; Adeno: adenocarcinoma; SRC: signet ring cell. IHC: immunohistochemistry; ECOG, Eastern Cooperative Oncology Gro
Figshare2015-12-02 更新20
Tumor number and volume of offspring at sacrifice (22 weeks).
Data expressed as Mean��SEM and differences between treatment groups were determined by one way ANOVA and appropriate post hoc test. Differences with a p*. n = number of mice/group, tumor volume expre
Figshare2015-12-02 更新10
Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)
PURPOSE: This randomized phase III trial is studying maintenance therapy with bevacizumab alone after an induction therapy combining bevacizumab+chemotherapy to see how well they work compared to main
NIAID Data Ecosystem40
Median overall survival and progression-free survival hazard ratios (HRs) and 95% Credible Intervals for cabazitaxel, abiraterone and enzalutamide using Bayesian fixed effects modeling.
Median overall survival and progression-free survival hazard ratios (HRs) and 95% Credible Intervals for cabazitaxel, abiraterone and enzalutamide using Bayesian fixed effects modeling.
NIAID Data Ecosystem20
